Adding a PD-1 inhibitor to standard of care improved disease-free survival (DFS) in stage III soft-tissue sarcoma of the ...

James McMahon – Kerrang! Editor from 2011 to 2017 – has died from soft tissue sarcoma.

Efti + KEYTRUDA combo shows strong efficacy for NSCLC patients in Immutep's phase 1 study. Read why IMMP stock may see upside ...

Immutep (IMMP) has released an update. Immutep Limited has announced promising results from its Phase II trial of eftilagimod alpha, combined ...

Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...

Media ReleaseEfti in combination with pembrolizumab and radiotherapy demonstrates significant efficacy in the neoadjuvant setting in patients ...

Tributes are being paid to former Kerrang! editor, music journalist and podcaster James McMahon, who passed away aged 44 on ...

Pembrolizumab, an immunotherapy medication, significantly enhanced disease-free survival when added to the standard of care ...

Adaptimmune’s Phase II IGNYTE-ESO trial investigating experimental T cell therapy lete-cel has achieved its primary endpoint.

PITTSBURGH — Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue ...

Shares of Immutep (NASDAQ:IMMP) climbed 11% Thursday after the Australian company reported positive data from two clinical trials of its drug candidate eftilagimod alpha, or efti. Immutep (IMMP) said ...

Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the ...